×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Skin Cancer

Featured Content
Kristie L. Kahl
“You have to speak up. What you don’t say is the most predictive of the care you don’t get.”
 
By Beth Fand Incollingo and Kristie L. Kahl
Patients can pick from a growing array of treatments, from same-day- results surgery to game-changing immunotherapy, to fight the most common type of cancer.
 
Ryan McDonald
The Food and Drug Administration approved Keytruda to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
 
Jessica Skarzynski
“The relapse-free survival curves for both treatment arms appear to be reaching a plateau, which is a good sign if we are talking about cure,” said lead study author Dr. Axel Hauschild.
Key opinion leaders close the discussion by considering the future of cutaneous squamous cell carcinoma (CSCC) and promising emerging regimens.
Experts in skin-care management discuss the role of the multidisciplinary team to provide patients with the best treatment strategy.
A discussion of the possibility of managing organ transplant populations with immunotherapy.
Experts in the treatment of skin cancers discuss the management of immunotherapy toxicities in the inpatient setting.
Key opinion leaders discuss the use of anti-PD1 therapy in managing patients with cutaneous squamous cell carcinoma (CSCC).
A discussion on the use of immunotherapy and surgery in locally advanced cutaneous squamous cell carcinoma (CSCC), and the decision factors for treatment selection.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×